Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 6Gastrointestinal 4Thoracic 2Other hematologic neoplasm 2NET 2Lymphoid 2Genitourinary 2Endocrine 2Breast 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 1Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Data Collection × Endocrine × 1 year × Clear all
NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting
150 enrolled
EndocrineNET

Intestinal Neuroendocrine Tumor

NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡